Cvergenx has developed an informatics-based approach to radiation treatment planning that enables radiation oncologists to personalize and optimize radiation therapy.
The company’s Precision Genomic Radiation Therapy platform (pGRT™) takes a mathematical, rather than empirical, approach to the integration of genomics into radiation treatment and planning. This unique application of medical mathematics is central to the Cvergenx patented Radiosensitivity Index (RSI) and Genomic Adjusted Radiation Dose (GARD). Combined, these parameters provide the first opportunity to adapt radiation treatment and dose to improve outcomes on a patient-by-patient basis.
We are now in the process of demonstrating how patients can benefit by integrating biological information into radiotherapy treatment plans to optimize dose on an individualized basis.